Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein detection, has announced an upcoming Investor & Analyst event scheduled for November 19, 2025 in New York City.
The event will feature presentations from key management team members, followed by a Q&A session. While the in-person event at the Hyatt Centric Times Square is by invitation, a live webcast will be available for virtual attendees from 10 AM to 12 PM ET.
Quantum-Si (Nasdaq: QSI), a proteomics technology company, has granted 17,033 restricted stock units (RSUs) to new employees as inducement awards under its 2023 Inducement Plan. The RSUs will vest over four years, with 25% vesting on September 20, 2026, followed by 12 quarterly installments, contingent on continued employment.
These equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and are specifically designed to attract new talent who were not previously Quantum-Si employees.
Quantum-Si (Nasdaq: QSI) has launched its new V4 Sequencing Kit, compatible with both Platinum® and Platinum® Pro instruments. The upgraded kit delivers an 85% increase in sequenceable peptides compared to the V3 version, featuring enhanced glycine recognition and improved alanine and serine detection capabilities.
Key advancements include the ability to sequence through proline-rich domains, expanded amino acid coverage, and improved sample mixture precision with 24-plex barcoding capabilities. The new kit particularly benefits antibody sequencing applications and complex mixture analysis in immunoprecipitation workflows.
Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein analysis, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place at the Lotte New York Palace Hotel from September 8-10, 2025.
The company's leadership, including President and CEO Jeff Hawkins and CFO Jeff Keyes, will conduct one-on-one meetings on September 9, 2025. Additionally, Jeff Hawkins will participate in a fireside chat at 10:00 AM ET on the same day. Investors can access the live and archived webcast through the company's website in the Investors section.
Quantum-Si (Nasdaq: QSI), a proteomics technology company, has announced the granting of 237,068 restricted stock units (RSUs) to new employees as inducement awards. The grants were made under the company's 2023 Inducement Equity Incentive Plan and approved by the Compensation Committee of QSI's Board of Directors.
The RSUs will follow a vesting schedule with 25% vesting on September 20, 2026, followed by the remaining amount vesting in 12 equal quarterly installments. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are specifically designed for new hires who were not previously QSI employees.
Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein detection, announced its participation in the upcoming UBS Precision Medicine Frontiers Summit. The event will take place at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA, from August 13-14, 2025.
CEO Jeff Hawkins and CFO Jeff Keyes will be available for one-on-one meetings on August 14. Additionally, Jeff Hawkins will participate in the New Dimensions in Proteomics and Cellular Research panel from 8:15 - 8:50 AM PDT on the same day.
Quantum-Si (Nasdaq: QSI), a proteomics technology company, reported its Q2 2025 financial results with revenue of $591,000 and a gross margin of 59%. First half 2025 revenue reached $1.4 million, showing a 33% increase year-over-year.
The company completed a $50 million capital raise through a registered direct offering, extending their cash runway into Q2 2028. Development programs remain on track, including the Proteus™ platform, v4 Sequencing Kit (Q3 2025 launch), and v3 Library Preparation Kit (Q4 2025 launch). However, NIH funding challenges have impacted capital sales, leading to new instrument acquisition options.
Q2 2025 saw a net loss of $28.8 million compared to $23.1 million in Q2 2024. Cash position stands at $214.2 million as of June 30, 2025.
Quantum-Si (Nasdaq: QSI), a proteomics technology company specializing in single-molecule protein analysis, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The event will take place at the InterContinental Boston Hotel from August 12-14, 2025.
The company's leadership, including President and CEO Jeff Hawkins and CFO Jeff Keyes, will conduct one-on-one meetings and participate in a fireside chat on August 12, 2025 at 4:00 PM ET. Investors can access the webcast through the company's website in the Investors section.
Quantum-Si (Nasdaq: QSI), a proteomics technology company focused on single-molecule protein analysis, has scheduled its second quarter 2025 financial results announcement for August 5, 2025.
The company will host a conference call at 4:30 PM ET on the same day, featuring CEO Jeff Hawkins and CFO Jeff Keyes. Investors can access the call through a live webcast on Quantum-Si's website or register for a personalized dial-in option.
Quantum-Si (Nasdaq: QSI), a proteomics technology company, has announced a $50 million registered direct offering of common stock. The company will sell 29,940,119 shares at $1.67 per share to a single institutional investor.
The offering is expected to close around July 8, 2025, subject to customary conditions. A.G.P./Alliance Global Partners is serving as the sole placement agent. The proceeds will be used for working capital and general corporate purposes. The offering is made through an effective shelf registration statement on Form S-3.